Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
Relatie tussen reduced intensity conditioneringsregimes en overleving bij NHL-patiënten
sep 2020 | Lymfoom, Stamceltransplantatie